Jingli Liu1, Biao Xu2, Tingmei Chen3, Jie Chen4, Jing Feng4, Chenyu Xu3, Lanhua Liu2, Yali Hu4, Yi-Hua Zhou5. 1. Department of Laboratory Medicine, Nanjing Drum Tower Hospital and Jiangsu Key Laboratory for Molecular Medicine, Nanjing University Medical School, Nanjing, China. 2. Department of Obstetrics and Gynecology, Taixing People's Hospital, Taixing, China. 3. Department of Obstetrics and Gynecology, Zhenjiang Fourth People's Hospital, Zhenjiang, China. 4. Department of Obstetrics and Gynecology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China. 5. Department of Laboratory Medicine, Nanjing Drum Tower Hospital and Jiangsu Key Laboratory for Molecular Medicine, Nanjing University Medical School, Nanjing, China; Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing Medical University, Nanjing, China. Electronic address: zgr03summer@126.com.
Abstract
BACKGROUND: We aimed to clarify whether presence of hepatitis B virus (HBV) markers in cord blood indicates exposure to or infection with HBV. METHODS: We prospectively recruited HBsAg-positive pregnant women and their neonates 2012 through 2015. All neonates received postnatal immunoprophylaxis. The infants were followed up at 7-14 months of age. RESULTS: Totally 329 HBsAg-positive pregnant women and 333 neonates were enrolled. No cord blood was anti-HBc IgM positive. A total of 290 (87.1%) neonates were followed up at 7-14 months of age and 6 (2.1%) of them were infected with HBV. Of 146 neonates born to HBeAg-negative mothers, 38 (26.0%) and 30 (20.5%) had detectable HBsAg and HBV DNA in cord blood respectively, but none of 126 infants followed up was infected. Of 187 neonates born to HBeAg-positive mothers, 92 (49.2%) and 79 (42.2%) had detectable HBsAg and HBV DNA in cord blood respectively; 6 (3.7%) of 164 infants followed up were infected. Of seven neonates with HBV DNA > 105 IU/ml in cord blood, four had no infection and three others were infected. CONCLUSION: Presence of HBsAg and/or HBV DNA, even at high levels, in cord blood just indicates exposure to, but not infection with HBV. Presence of HBV markers in cord blood cannot define intrauterine infection.
BACKGROUND: We aimed to clarify whether presence of hepatitis B virus (HBV) markers in cord blood indicates exposure to or infection with HBV. METHODS: We prospectively recruited HBsAg-positive pregnant women and their neonates 2012 through 2015. All neonates received postnatal immunoprophylaxis. The infants were followed up at 7-14 months of age. RESULTS: Totally 329 HBsAg-positive pregnant women and 333 neonates were enrolled. No cord blood was anti-HBc IgM positive. A total of 290 (87.1%) neonates were followed up at 7-14 months of age and 6 (2.1%) of them were infected with HBV. Of 146 neonates born to HBeAg-negative mothers, 38 (26.0%) and 30 (20.5%) had detectable HBsAg and HBV DNA in cord blood respectively, but none of 126 infants followed up was infected. Of 187 neonates born to HBeAg-positive mothers, 92 (49.2%) and 79 (42.2%) had detectable HBsAg and HBV DNA in cord blood respectively; 6 (3.7%) of 164 infants followed up were infected. Of seven neonates with HBV DNA > 105 IU/ml in cord blood, four had no infection and three others were infected. CONCLUSION: Presence of HBsAg and/or HBV DNA, even at high levels, in cord blood just indicates exposure to, but not infection with HBV. Presence of HBV markers in cord blood cannot define intrauterine infection.
Authors: Jodie Dionne-Odom; Gabriella D Cozzi; Ricardo A Franco; Basile Njei; Alan T N Tita Journal: Am J Obstet Gynecol Date: 2021-09-10 Impact factor: 8.661
Authors: Karin Geffert; Tongai G Maponga; Shimba Henerico; Wolfgang Preiser; Stella Mongella; August Stich; Samuel Kalluvya; Andreas Mueller; Christa Kasang Journal: BMC Infect Dis Date: 2020-06-05 Impact factor: 3.090